Na Meng

Na Meng

Auto-generated profile, based on publicly available information

Na Meng

Department of Radiation Oncology, Cancer center, Peking University Third Hospital, No. 49 North Garden road, Haidian district, Beijing, 100191, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
PJPing Jiang
Ping Jiang
EREn Y Rao
En Y Rao
NMNa Meng
Na Meng
Yong ZhaoYong Zhao
Yong Zhao
JWJun J Wang
Jun J Wang
The microRNA-17-92 (miRNA-17-92) cluster, at chromosome 13q31-q32, also known as oncomir-1, consists of seven miRNAs that are transcribed as a polycistronic unit. Over-expression of miRNA-17-92 has been observed in lymphomas and other solid tumors. Whether miRNA-17-92 expression affects the response of tumor cells to radiotherapy is not addressed so far. In the present study, we studied the effects of miRNA-17-92 on the radiosensitivity of human mantle cell lymphoma (MCL) cells Z138c. Over-expression of miRNA-17-92 significantly increased survival cell number, cell proliferation and decreased cell death of human MCL cells after different doses of radiation. Immunoblot analysis showed that phosphatase and tension homolog (PTEN) and PHLPP2 was down-modulated and pAkt activity was enhanced in MCL cells after over-expressing miRNA-17-92 after irradiation. These findings are the first direct evidence that over-expression of miRNA-17-92 cluster significantly increases the radioresistance of human MCL cells, which offers a novel target molecule for improving the radiotherapy of MCL in clinic.

23 December 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
QCQianqian Cao
Qianqian Cao
HWHao Wang
Hao Wang
NMNa Meng
Na Meng
YJYuliang Jiang
Yuliang Jiang
PJPing Jiang
Ping Jiang
KZKaixian Zhang
Kaixian Zhang
Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors. From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90–183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was calculated by the Kaplan-Meier method. For 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with a median of 34 months (range, 4–39 months). For 4 chordomas, the local control rate was 50% with a median follow-up of 13 months (range, 3–17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy. Percutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors.


1 May 2012 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JWJ. Wang
J. Wang
LZL. Zhu
L. Zhu
YJY. Jiang
Y. Jiang
NMN.A. Meng
N.A. Meng
WRW. Ran
W. Ran
RYR. Yang
R. Yang

1 May 2012 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JWJ.J. Wang
J.J. Wang
LLL.E.I. Lin
L.E.I. Lin
YJY. Jiang
Y. Jiang
NMN.A. Meng
N.A. Meng
WRW. Ran
W. Ran
YYY.A.N. Yu
Y.A.N. Yu

23 September 2014
Verified
Journal Article
Closed access
JFJinghong Fan
Jinghong Fan
YGYang Gao
Yang Gao
LLLei Lin
Lei Lin
JWJunjie Wang
Junjie Wang
NMNa Meng
Na Meng
HYHailin Yao
Hailin Yao